<DOC>
	<DOCNO>NCT02388295</DOCNO>
	<brief_summary>AZD3241 myeloperoxidase ( MPO ) inhibitor trial assess safety tolerability , randomize trial , patient Multiple System Atrophy .</brief_summary>
	<brief_title>AZD3241 PET MSA Trial , Phase 2 , Randomized,12 Week Safety Tolerability Trial With PET MSA Patients</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<criteria>1 . Male female , age 3080 year , inclusive , screen . 2 . Meet criteria diagnosis probable possible MSA accord consensus criterion ( Gilman et al . 2008 ) . 3 . `` Highaffinity binder '' `` mixedaffinity binder '' TSPO , confirm prospective genotyping TSPO polymorphism screen . 4 . Subjects must understand nature study must provide sign dated write informed consent accordance local regulation conduct studyrelated procedure . The informed consent reflect protocol stipulation concern use contraception . 5 . Medical treatment MSA comorbid medical condition must stable least 30 day prior screen screen baseline . 6 . Written oral fluency local language . 7 . Able willing participate schedule evaluation , abide study restriction , complete require test procedure . 8 . In opinion investigator , subject must consider likely comply study protocol high probability complete study . 9 . Able swallow tablet whole . 1 . Prior participation AZD3241 study . 2 . Magnetic resonance imaging ( MRI ) perform screen consistent diagnosis MSA . 3 . Received PET scan within last 12 month . 4 . Negative Allen test hand , unless brachial artery use arterial cannulation . 5 . Subjects determine `` low affinity binder '' TSPO genotyping . 6 . Claustrophobia would contraindicate brain MRI scan brain PET scan . 7 . Pregnancy , lactation , , female childbearing potential , positive serum βhCG screen positive urine βhCG baseline ( Day 1 ) . 8 . Initiation change pharmacologic therapy symptom MSA within 30 day prior screen screen baseline ( Day 1 ) . 9 . Significant neurological disease affect central nervous system ( CNS ) , MSA 10 . History brain surgery parkinsonism . 11 . History stem cell treatment . 12 . Seizure disorder , unless well control treatment stable least 30 day prior screen screen baseline ( Day 1 ) . 13 . Presence clinically significant medical condition 14 . History presence thyroid disease . 15 . Any abnormal TSH Free T4 test result screen baseline ( Day 1 ) . 16 . History presence gastrointestinal disorder disease know interfere absorption , distribution , metabolism excretion drug 17 . History presence renal disease impair renal function . 18 . A QT interval correct accord Fridericia procedure ( QTcF ) interval measurement &gt; 450 msec screen ( single ECG ) baseline ( Day 1 ) ( mean three ECG measurement ) family history longQT syndrome . 19 . Uncontrolled hypertension 20 . History presence diabetes , unless glucose level well control treatment stable least 30 day prior screen screen baseline ( Day 1 ) . 21 . History cancer within last 5 year , exception nonmetastatic basal cell carcinoma skin . 22 . Any clinically important abnormality , determine investigator , physical examination vital sign , ECG , clinical laboratory test result abnormality due stable , wellcontrolled medical condition ; abnormality could detrimental subject could compromise study . 23 . Use potent inhibitor CYP3A4 , Use potent inducer CYP3A4 and/or Use drug mainly metabolize CYP3A4 24 . Treatment investigational drug device within 60 day five halflives prior screen , whichever longer , screen baseline ( Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Multiple System Atrophy ( MSA ) , PET imaging , myeloperoxidase ( MPO ) inhibitor</keyword>
</DOC>